Skip to content

Author

Weam A. Elkady

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Activated platelets in multiple sclerosis: Immunoinflammatory mechanisms and the therapeutic controversy of acetylsalicylic acid.

A narrative review explores how platelet activation may contribute to MS through blood-brain barrier dysfunction, immune-cell recruitment, oxidative stress, demyelination, and neurodegeneration, and critically examines acetylsalicylic acid (ASA) as a potential platelet-targeted strategy.

H. Al-Jehani, Hayder M. Al-kuraishy, Weam A. Elkady et al. · 0 citations
Review Open access Sep 2026

Platelet-activating factor in multiple sclerosis: From peripheral inflammation to central neurodegeneration.

PAF/PAF-R targeting remains a mechanistically promising but clinically unestablished therapeutic approach requiring further translational investigation, and some detrimental effects of PAF appear to occur independently of PAF-R.

A. Baothman, Hayder M. Al-kuraishy, Weam A. Elkady et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.